

August 25, 2020

BSE Limited

Corporate Relationship Department
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400 001.

National Stock Exchange of India Limited

Listing Department
Exchange Plaza, Bandra-Kurla Complex,
Bandra (East),
Mumbai – 400 051.

Scrip code: **512529**

Symbol: **SEQUENT**

Dear Sir/Madam,

Sub: Board reconstitution

Pursuant to Regulation 30 (read with Part A of Schedule III) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to update the changes in Board of Directors, as under:

- Mr. Neeraj Bharadwaj (DIN: 01314963) and Mr. Rahul Mukim (DIN: 06996915) who were appointed as Additional Directors (Non-Executive Non Independent) of the Company on August 17, 2020, automatically ceased to be Directors on conclusion of the 35th Annual General Meeting held today, in terms of Section 161 of the Companies Act, 2013 (“Act”). Section 161 of the Act read with the Articles of Association of the Company provides that an Additional Director appointed by the Board shall hold office up to the date of the next Annual General Meeting or the last date on which the Annual General Meeting should have been held, whichever is earlier.

Further, at the Board Meeting held today, immediately after the Annual General Meeting, the Board considered and approved/ noted the following changes in Directorship:

1. Appointment of Mr. Neeraj Bharadwaj (DIN: 01314963) and Mr. Rahul Mukim (DIN: 06996915) as Additional (Non-Executive Non-Independent) Directors of the Company w.e.f. August 25, 2020 to hold office as such until the conclusion of ensuing Annual General Meeting of the Company.

Mr. Neeraj Bharadwaj and Mr. Rahul Mukim have been nominated by CA Harbor Investments (Part of The Carlyle Group) as their nominee on the Board of the Company.

SeQuent Scientific Limited

Registered Office: 301, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Area, Thane (W), Mumbai - 400604, India

Tel: +9122 4111777 | CIN: L99999MH1985PLC036685

<http://www.sequent.in>

2. Appointment of Dr. Kamal K Sharma (DIN: 00209430) and Mr. Milind Sarwate (DIN: 00109854) as an Independent Directors of the Company w.e.f. August 25, 2020 for a period of five consecutive years from the date of appointment.
3. Resignation of Dr. Gopakumar Nair, Chairman and Independent Director of the Company effective immediately.

The Board of Directors noted Dr. Nair's resignation and places on record its appreciation for the immense contribution and valuable guidance given by Dr. Nair during his tenure.

Brief profile and other Information of aforesaid Directors pursuant to SEBI Circular bearing reference CIR/CFD/CMD/4/2015 dated September 9, 2015 is mentioned in '**Annexure A**' as enclosed herewith.

We request you to take the above on record.

Thanking you,

Yours faithfully,
For **Sequent Scientific Limited**



Krunal Shah
Company Secretary & Compliance Officer



Encl.: A/a

Annexure A

1. Appointment of Mr. Neeraj Bharadwaj as a Director of the Company

Sr. No.	Particulars	Details of Change
1.	Reason for change. viz. appointment, resignation, removal, death or appointment otherwise	<p>Mr. Neeraj Bharadwaj (DIN: 01314963) appointed as an Additional (Non-Executive Non-Independent) Director of the Company.</p> <p>Mr. Neeraj Bharadwaj is a nominee of CA Harbor Investments (part of The Carlyle Group) on the Board of the Company.</p>
2.	Date of appointment	August 25, 2020
3.	Term of appointment	Till the conclusion of the next Annual General Meeting. His office is liable to retire by rotation.
4.	Brief profile (in case of appointment)	<p>Mr. Neeraj Bharadwaj is the Managing Director of Carlyle India Advisors Private Limited, focused on large growth capital and buyout opportunities across sectors in India. He is based in Mumbai.</p> <p>Prior to joining Carlyle in 2012, Mr. Bharadwaj was the Managing Director with Accel Partners' growth investing operation in India. Preceding that he was with Apax Partners for nearly 10 years – as a Partner in the U.S. and subsequently as Managing Director/Country Head for Apax in India, where he led the India operations. Investments he has been involved with include Apollo Hospitals (BSE: AHEL), Jamdat (NASDAQ: JMDT), Widerthan (NASDAQ: WTHN), NXP and others. Previously, Mr. Bharadwaj was an engagement manager at McKinsey & Co.</p> <p>Mr. Bharadwaj was selected as Board Member of the Indian School of Business (ISB), a Young Global Leader of the World Economic Forum (WEF), Board Member of Olympic Gold Quest (OGQ), and Member of the Harvard Business School South Asia Advisory Board.</p> <p>Mr. Bharadwaj serves on the boards of Global Health Private Limited, VXI Global Solutions and Delhivery Logistics.</p>

SeQuent Scientific Limited

Registered Office: 301, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Area, Thane (W), Mumbai - 400604, India

Tel: +9122 4111777 | CIN: L99999MH1985PLC036685

<http://www.sequent.in>

		Mr. Bharadwaj holds an MBA with distinction from Harvard Business School, and graduated summa cum laude with a BS in economics from the Wharton School of the University of Pennsylvania.
5.	Disclosure of relationships between directors (in case of appointment of Director)	Mr. Neeraj Bharadwaj does not have any <i>inter-se</i> relationship with other Directors of the Company.

2. Appointment of Mr. Rahul Mukim as a Director of the Company

Sr. No.	Particulars	Details of Change
1.	Reason for change. viz. appointment, resignation, removal, death or appointment otherwise	Mr. Rahul Mukim (DIN: 06996915) appointed as an Additional (Non-Executive Non-Independent) Director of the Company. Mr. Rahul Mukim is a nominee of CA Harbor Investments (part of The Carlyle Group) on the Board of the Company.
2.	Date of appointment	August 25, 2020
3.	Term of appointment	Till the conclusion of the next Annual General Meeting. His office is liable to retire by rotation.
4.	Brief profile (in case of appointment)	Mr. Rahul Mukim is a Director of the Carlyle Group focused on India buyout opportunities and is based in Mumbai. Prior to joining Carlyle, Mr. Rahul was a Director at Olympus Capital, where he looked at India focused growth investments in healthcare and financial services. Prior to that, Rahul worked at Morgan Stanley's hedge fund called Frontpoint and at ICICI venture (an India focused Private Equity Fund). Mr. Rahul has received an MBA degree from IIM Lucknow and a degree in computer engineering from VJTI Mumbai.
5.	Disclosure of relationships between directors (in case of appointment of Director)	Mr. Rahul Mukim does not have any <i>inter-se</i> relationship with other Directors of the Company.

SeQuent Scientific Limited

Registered Office: 301, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Area, Thane (W), Mumbai - 400604, India

Tel: +9122 4111777 | CIN: L99999MH1985PLC036685

<http://www.sequent.in>

3. Appointment of Dr. Kamal K Sharma as an Independent Director of the Company

Sr. No.	Particulars	Details of Change
1.	Reason for change. viz. appointment, resignation, removal, death or appointment otherwise	Dr. Kamal K Sharma (DIN: 00209430) appointed as an Additional (Non-Executive Non-Independent Director) of the Company.
2.	Date of appointment	August 25, 2020
3.	Term of appointment	For a period of 5 consecutive years from the date of appointment.
4.	Brief profile (in case of appointment)	Dr. Kamal Sharma is currently the Non-Executive Vice-Chairman of Lupin and has over 48 years of professional experience in executive positions in the Chemical and Pharmaceutical industries and has essayed a wide variety of roles in operations, corporate development and executive management. As the Managing Director of Lupin for a decade between 2003-13, he was instrumental in Lupin achieving leadership position in key markets and businesses, transforming it into one of the largest and fastest growing pharmaceutical companies globally. Previously, he also served as President & Chief Executive of the Life Sciences and speciality group and Member of the Management Board at RPG Enterprises. Mr. Sharma received a Bachelors Degree in Chemical Engineering from IIT Kanpur, a post graduate diploma in Industrial Management from Jamnalal Bajaj Institute of Management Studies and a PhD in Economics from IIT, Mumbai. He has also attended Advanced Management Program (AMP) at Harvard Business School, Boston.
5.	Disclosure of relationships between directors (in case of appointment of Director)	Dr. Kamal Sharma does not have any <i>inter-se</i> relationship with other Directors of the Company.

SeQuent Scientific Limited

Registered Office: 301, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Area, Thane (W), Mumbai - 400604, India

Tel: +9122 4111777 | CIN: L99999MH1985PLC036685

<http://www.sequent.in>

4. Appointment of Mr. Milind Sarwate as an Independent Director of the Company

Sr. No	Particulars	Details of Change
1.	Reason for change. viz. appointment, resignation, removal, death or appointment otherwise	Mr. Milind Sarwate (DIN: 00109854) appointed as an Additional (Non-Executive Non-Independent Director) of the Company.
2.	Date of appointment	August 25, 2020
3.	Term of appointment	For a period of 5 consecutive years from the date of appointment.
4.	Brief profile (in case of appointment)	Mr. Milind Sarwate is the Founder & CEO of Increate Value Advisors LLP and provides advice & mentorship in value creation, effective governance and capability building, leveraging his 37-year experience including long stints in Marico & Godrej. He also invests in promising businesses/social enterprises. A Chartered Accountant, Cost Accountant, Company Secretary and a CII-Fulbright Fellow, Mr. Sarwate has eight independent directorships which include five listed companies - Mahindra Finance, Hexaware, Glenmark, Metropolis Healthcare and Matrimony.com, all with an audit committee role.
5.	Disclosure of relationships between directors (in case of appointment of Director)	Mr. Milind Sarwate does not have any <i>inter-se</i> relationship with other Directors of the Company.

SeQuent Scientific Limited

Registered Office: 301, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Area, Thane (W), Mumbai - 400604, India

Tel: +9122 4111777 | CIN: L99999MH1985PLC036685

<http://www.sequent.in>

5. Cessation of Dr. Gopakumar Nair as Director of the Company

Sr. No	Particulars	Details of Change
1.	Reason for change. viz. appointment, resignation, removal, death or appointment otherwise	Consequent to acquisition of 25.2% of the share capital of the Company by CA Harbor Investments and appointment of their nominee directors on the Board of the Company, Dr. Gopa Kumar Nair has tendered his resignation from the Directorship of the Company.
2.	Date of Cessation	August 25, 2020
3.	Term of appointment	N.A.
4.	Brief profile (in case of appointment)	N.A.
5.	Disclosure of relationships between directors (in case of appointment of Director)	N.A.

SeQuent Scientific Limited

Registered Office: 301, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Area, Thane (W), Mumbai - 400604, India

Tel: +9122 4111777 | CIN: L99999MH1985PLC036685

<http://www.sequent.in>